Chimerix to Present at Maxim Group 2022 Virtual Growth Conference

Rhea-AI Summary

Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present a pre-recorded talk at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022. An audio webcast of the presentation will be accessible on Chimerix's Investor Relations website and archived for 90 days. Chimerix focuses on developing medicines for severe diseases, having received FDA approval for TEMBEXA to treat smallpox. The company's advanced clinical programs include ONC201 for glioma and dociparstat sodium (DSTAT) for acute myeloid leukemia.

DURHAM, N.C., March 21, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference taking place March 28-30, 2022.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. In June 2021, the U.S. Food and Drug Administration granted approval of TEMBEXA for the treatment of smallpox as a medical countermeasure. The Company has two other advanced clinical-stage development programs, ONC201 and dociparstat sodium (DSTAT). ONC201 is in development for recurrent H3 K27M-mutant glioma as its lead candidate. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia.

CONTACT:
Investor Relations:        
Michelle LaSpaluto
919 972-7115
ir@chimerix.com  

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com 

 

FAQ

When will Chimerix present at the Maxim Group 2022 Virtual Growth Conference?

Chimerix CEO Mike Sherman will present at the Maxim Group 2022 Virtual Growth Conference from March 28-30, 2022.

How can I access Chimerix's presentation from the conference?

The audio webcast of Chimerix's presentation will be available on their Investor Relations website and archived for approximately 90 days.

What is the mission of Chimerix?

Chimerix aims to develop medicines that significantly improve and extend the lives of patients facing life-threatening diseases.

What recent FDA approval did Chimerix receive?

In June 2021, Chimerix received FDA approval for TEMBEXA for the treatment of smallpox.

What are the main clinical programs currently under development by Chimerix?

Chimerix is developing ONC201 for recurrent H3 K27M-mutant glioma and dociparstat sodium (DSTAT) for acute myeloid leukemia.